公司概况 - 公司是一家专注于利用脂质纳米晶（LNC）平台递送技术开发突破性疗法的临床阶段生物制药公司[465] 财务表现 - 2023年和2022年公司的净亏损分别为22,942美元和20,997美元，公司预计在可预见的未来将继续亏损[469] - 2023年公司通过与BioNTech SE和Genentech Inc.的研究合作产生了1,096美元的合同研究收入[470] - 研发支出主要包括产品候选物MAT2203的开发成本，LNC平台的推进成本，以及与CROs等合作的费用[471] - 2023年公司的研发支出为14,489美元，较2022年的16,678美元有所下降，主要是由于临床试验费用和专业咨询费用的减少[472] - 2023年公司的一般和行政支出为10,373美元，较2022年的11,100美元有所下降，主要是由于某些保险费用的降低和与项目相关的咨询费用和设施费用的降低[473] 现金流和资金状况 - 公司截至2023年12月31日的现金、现金等价物和可交易债务证券总额为13,756美元[488] - 2023年公司的经营活动产生的现金流为15,278美元的负数，较2019年的19,156美元的负数有所减少[490] - 2023年和2022年的融资活动中，融资活动净现金流分别为-7和79美元[492] 风险和展望 - 公司预计未来将继续承担重大费用和增加运营亏损，可能需要通过私人和公共股权发行、债务融资、政府或其他第三方资金、合作和许可安排来满足现金需求[493][494][495][496][497] - 公司的财务状况和运营结果可能受到全球供应链中断、全球贸易争端和/或政治不稳定等无法控制的因素的影响[498]

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. [Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 (Address of principal executive of ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerry Jabbour - Chief Executive Officer Terry Matkovits - Chief Development Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Operator Welcome to the Matinas BioPharma Second Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management’s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juris ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Jody Cain – LHA Investor Relations Jerry Jabbour – Chief Executive Officer Terry Matkovits – Chief Development Officer Terry Ferguson – Chief Medical Officer Keith Kucinski – Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Operator Greetings and welcome to the Matinas BioPharma First Quarter 2023 Conference Call and Webcast. [Operator Instructions] As a remin ...

May 10, 2023 BIOPHARMA www.matinasbiopharma.com NYSE American: MTNB Lipid Nanocrystals™ (LNCs) 3 Matinas Has Developed Two Distinct Platforms for Delivering Therapeutic Cargo Phosphatidylserine and its Unique Properties Link Both Platforms 4 Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform Stable, phospholipidcalcium crystalline nanocrystals Extra-hepatic targeting • Validated Blood-Brain-Barrier penetration (MAT2203) Safe & stable • No evidence of immunogenicity or cytotoxi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Jody Cain - Investor Relations Jerry Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Matkovits - Chief Development Officer Conference Call Participants Greg Fraser - Truist Securities Operator Greetings and welcome to the Matinas BioPharma 2022 Fourth Quarter and Full Year Conference Call. [Operator Instructions] As a reminder, this conference is being ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other jurisdicti ...